^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    emiltatug ledadotin (XMT-1660)

    i
    Other names: XMT-1660
    Company:
    Mersana
    Drug class:
    Tubulin inhibitor, B7-H4-targeted antibody-drug conjugate
    Related drugs:
    10ms
    A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=319, Recruiting, Mersana Therapeutics | N=166 --> 319 | Trial completion date: Jan 2026 --> May 2027 | Trial primary completion date: Jan 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    emiltatug ledadotin (XMT-1660)
    1year
    A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=166, Recruiting, Mersana Therapeutics
    Trial completion date • Trial primary completion date
    |
    emiltatug ledadotin (XMT-1660)
    over1year
    Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. (PubMed, Mol Cancer Ther)
    In a panel of 28 breast cancer patient-derived xenografts (PDX), XMT-1660 demonstrated activity that correlated with B7-H4 expression. XMT-1660 has recently entered clinical development in a Phase 1 study (NCT05377996) in cancer patients.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    VTCN1 underexpression
    |
    emiltatug ledadotin (XMT-1660)
    over1year
    XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers. (ASCO 2023)
    XMT-1660 is a B7-H4-directed Dolasynthen antibody drug conjugate designed with a precise, optimized drug-to-antibody ratio and a DolaLock microtubule inhibitor payload with controlled bystander effect. NCT05377996. Clinical trial information: NCT05377996.
    P1 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression • VTCN1 overexpression
    |
    emiltatug ledadotin (XMT-1660) • GM.CD40L cell vaccine
    almost2years
    XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (SGO 2023)
    No abstract available
    P1 data
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    emiltatug ledadotin (XMT-1660)
    2years
    XMT-1660: A Phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers (SABCS 2022)
    The trial is currently enrolling patients. NCT05377996
    P1 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression • VTCN1 overexpression
    |
    emiltatug ledadotin (XMT-1660)
    over2years
    XMT-1660: A PHASE 1B TRIAL OF A B7-H4 TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN ENDOMETRIAL, OVARIAN, AND BREAST CANCERS (IGCS 2022)
    Trial in progress
    P1 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative
    |
    emiltatug ledadotin (XMT-1660)
    almost3years
    Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer (AACR 2022)
    XMT-1660 elicits a range of anti-tumor activity across a series of primary breast cancer xenograft models. XMT-1660 is currently in IND-enabling studies and is expected to enter a Phase I dose escalation clinical study in 2022. The efficacy/expression relationship of B7-H4 will be further evaluated in an upcoming clinical study with a goal to identify patients most likely to respond to XMT-1660.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    PD-L1 expression • ER positive • VTCN1 underexpression
    |
    emiltatug ledadotin (XMT-1660)